Form 8-K TG THERAPEUTICS, INC. For: Mar 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Sees Strong Results in 2016
March 8, 2016 11:41 AM ESTRoth Capital reaffirms TG Therapeutics (Nasdaq: TGTX) with a Buy (and Focus Pick) rating and $33 price target following the company's FY15 results report, which was made late Monday.
Joseph Pantginis, Ph.D., commented, The GENUINE Phase III (under SPA) is now enrolling at >150 U.S. sites and complete enrollment is expected by year-end and top-line data in early 2017. TG... More
TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share
March 7, 2016 4:03 PM ESTTG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More